How the Pharmaceutical industry can use this time to transform
While the pharmaceutical industry is less vulnerable to market dynamics during a downturn as compared to other industries, this unpredictable environment amid the COVID-19 pandemic has pharma reconsidering their portfolios and pipeline assets, supply chains, API sourcing, and manufacturing.
In this article, Arda Ural, Ph.D., a Principal and the Americas Industry Markets Leader, Health Sciences and Wellness at Ernst & Young LLP, provides interesting insights on market dynamics, enduring therapeutic areas, near term M&A for pharma/biopharma, and how the industry can use this time for transformation in commercial, supply chain and product development.
Read the full article HERE
COVID-19 and PharmaPrevious Post
The science of healthy ageingNext Post